Codexis, Inc. - CDXS STOCK NEWS

Codexis, Inc. (CDXS) reported a 23% increase in total revenue for Q1 2021, totaling $18.0 million, with product revenue doubling to $10.2 million. Notable growth was seen in the Performance Enzymes segment, which generated $14.2 million. The company's gross margin on product sales improved to 59%, up from 50% last year. Despite this growth, Codexis reported a net loss of $9.1 million or $0.14 per share. For 2021, the company maintains revenue guidance between $82 million and $85 million.

Codexis, Inc. (Nasdaq:CDXS) announced that it will report its Q1 2021 financial results on May 6, 2021, after market close. A conference call and webcast will occur at 4:30 p.m. ET to discuss the results and provide updates. The live webcast will be accessible via the Codexis Investor Relations website and archived for 90 days. Participants can also join by phone. Codexis leverages its CodeEvolver® technology for enzyme engineering in pharmaceuticals, fine chemicals, and diagnostics, emphasizing sustainable manufacturing.

Codexis, Inc. (CDXS) reported a strong fiscal year 2020, achieving total revenues of $69.1 million, marking a 1% increase from 2019. Product revenues rose to $30.2 million, boosted by higher sales of branded pharmaceutical products. The company achieved its highest product gross margin at 54.5%. R&D expenses increased to $44.2 million, while the net loss for the year was $24.0 million, or $0.40 per share. For 2021, Codexis forecasts total revenues between $82-85 million and product revenues between $36-39 million, with a gross margin of 54-58%.

Codexis, based in Redwood City, California, will present at three virtual investment conferences in late February and March 2021. Key events include the SVB Leerink Global Healthcare Conference on February 26 at 1:40 p.m. ET, the Cowen Health Care Conference on March 4 at 12:50 p.m. ET and 2:50 p.m. ET, and the H.C. Wainwright Life Sciences Conference on March 9-10. Live webcasts will be accessible on the company's Investor Relations webpage, with replays available for 30 days. Codexis specializes in enzyme engineering and sustainable manufacturing solutions.

Codexis, a leader in enzyme engineering, announced it will release its fourth quarter and full year 2020 financial results on February 25, 2021, post-market. Following the announcement, management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the live webcast through the Codexis Investor Relations website, and a replay will be available for 48 hours. Codexis uses its proprietary CodeEvolver technology for developing biocatalysts across pharmaceuticals and diagnostics.

Codexis (Nasdaq:CDXS) announced plans to expand operations with a new 36,000 square foot facility in San Carlos, CA, under a ten-year lease. This strategic move aims to enhance research and development capabilities, accommodating around 90 employees. The facility is expected to be ready by Q4 2021. CEO John Nicols highlighted the company's rapid growth in life sciences and sustainable manufacturing, anticipating continued acceleration through new partnerships and self-funded clinical programs.

Codexis (Nasdaq:CDXS) announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding the board to ten members. Dr. Martinborough brings over two decades of experience in drug discovery and development, having played a key role in the successful approval of Zeposia® for Multiple Sclerosis. Currently the Senior Vice President of Research at Escient Pharmaceuticals, her expertise is expected to contribute significantly to Codexis’ Biotherapeutics initiatives, enhancing its product development capabilities.

Codexis (CDXS) has extended its collaboration with Tate & Lyle, focusing on advancing the production of the DOLCIA PRIMA® Allulose and TASTEVA® M Stevia Sweetener. This partnership aims to improve production efficiencies through novel enzyme products developed by Codexis, potentially reducing costs linked to these sweeteners. Tate & Lyle’s new offerings target healthier consumer options, addressing diabetes and obesity issues. The collaboration, ongoing for seven years, underscores the importance of Codexis's enzyme technology in supporting Tate & Lyle's product development.

Codexis (Nasdaq:CDXS) announces that President and CEO John Nicols will participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The recorded session will be accessible starting January 11 at 6:00 a.m. ET on the company's investor website, available for 30 days. Codexis specializes in protein engineering, utilizing its CodeEvolver® technology to enhance protein performance for pharmaceuticals, enzymes, and diagnostics, promoting sustainable manufacturing processes.